Swiss pharma giant Roche Holding AG RHHBY posted strong growth in the third quarter. Sales increased 6% year over year to CHF 15.1 billion and were up 9% at constant exchange rates (CER).
The undisputed star of Roche’s pharma portfolio in the first quarter of this year is eye disease therapy Vabysmo, heading for blockbuster territory after posting sales of CHF 432 million ($485 ...
Incumbents Jacqueline A. McAlister and Christopher M. Halliday are running with Charles V. Roche III unopposed for three seats on the city’s Board of Education. Incumbent Margaret Day ...
Roche’s competition in the eye disease space is intensifying with Regeneron’s high-dose Eylea and a looming biosimilar challenge, but the Swiss pharma said its ...
Credit: Prostock-studio / Shutterstock. Swiss pharmaceutical company Roche has released positive topline one-year findings from a Phase IV trial of Vabysmo (faricimab) to treat diabetic macular oedema ...
0.1 mg/mL bovine serum albumin (BSA). Samples were loaded on a 4% acrylamide gel (acrylamide:bisacrylamide 29:1, 0.3× TBE) and migrated in 0.3× TBE for 30–70 min at 200 V. The gel was visualized using ...
a Gold-standard 0.143 FSC resolution calculated with 3DFSC (Tan et al, 2017). The masks for FSC calculation were generated in CryoSPARC using a relative threshold of 0.5. b Gold-standard 0.143 FSC ...
Swiss pharma giant Roche (ROG: SIX) on Friday released positive top-line one-year results from the open-label, single-arm phase IV ELEVATUM study evaluating Vabysmo (faricimab) for the treatment of ...
1 efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies. Roche announced positive topline one-year results from the open-label, single-arm phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback